How Jackson’s Q1 Loss, Annuity Momentum and TPG Deal At Jackson Financial (JXN) Has Changed Its Investment Story

• In early May 2026, Jackson Financial Inc. reported first-quarter 2026 results showing revenue of US$2,902 million and a net loss of US$424 million, while also continuing to return capital through dividends and share repurchases under its multi-year buyback program.
• Beneath the headline loss, the company highlighted strong retail annuity momentum, a very large share repurchase completion since 2021, and a new TPG partnership aimed at supporting product diversification and capital generation.
• We’ll now examine how robust retail annuity sales growth and the new TPG partnership may reshape Jackson Financial’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

Jackson Financial Investment Narrative Recap

To own Jackson Financial, you have to believe its retail annuity engine and capital-light diversification can outweigh volatile GAAP results and hedging noise. The latest quarter reinforces that tension: a sizeable GAAP net loss alongside strong retail annuity sales and capital returns. Near term, the key catalyst is continued growth in RILA and fixed indexed annuities, while the biggest risk remains pressure on the legacy variable annuity block and the asset risks tied to higher yielding investments. The Q1 news does not appear to change that balance in a material way.

Among the recent announcements, the completion of roughly 43.7% of shares repurchased since 2021, alongside reaffirmed common and preferred dividends, is especially relevant. It underlines management’s commitment to capital returns even as GAAP earnings remain volatile, which ties directly into the thesis that disciplined capital management can help offset earnings lumpiness and support the shift toward more diversified, spread based products.

Yet even with strong annuity sales and aggressive buybacks, investors should be aware of how higher yielding assets and variable annuity outflows could...

Read the full narrative on Jackson Financial (it's free!)

Jackson Financial's narrative projects $8.4 billion revenue and $880.0 million earnings by 2029. This requires 7.7% yearly revenue growth and an $897.0 million earnings increase from -$17.0 million today.

Uncover how Jackson Financial's forecasts yield a $124.75 fair value, a 13% upside to its current price.

Exploring Other Perspectives

The more cautious analysts paint a very different picture for you, even before this quarter’s results, assuming slower revenue growth around US$8.4 billion and earnings of about US$825 million by 2029, and highlighting how elevated variable annuity outflows might pressure cash flow compared with the current retail annuity growth story.

Explore 3 other fair value estimates on Jackson Financial - why the stock might be worth 42% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Jackson Financial research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Jackson Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Jackson Financial's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com